A year af­ter scor­ing FDA ap­proval for di­a­betes drug, Zealand touts pos­i­tive PhI­II da­ta for new in­di­ca­tion

When Ze­ga­logue, al­so known as dasiglucagon, got ap­proved by the FDA ear­ly last year for se­vere hy­po­glycemia in di­a­betes pa­tients, Zealand Phar­ma said that wasn’t the end of its vi­sion for the drug. One of the oth­er in­di­ca­tions they planned to pur­sue came in pe­di­atric pa­tients who had con­gen­i­tal hy­per­in­sulin­ism, a ge­net­ic dis­or­der where the pan­creas pro­duces too much in­sulin that re­sults in low blood sug­ar.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER